Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction

Inflamm Res. 2012 Jul;61(7):725-34. doi: 10.1007/s00011-012-0466-2. Epub 2012 Mar 24.

Abstract

Objective: To assess the usefulness of in-hospital measurement of C-reactive protein (CRP) concentration in comparison to well-established risk factors as a marker of post-infarct left ventricular systolic dysfunction (LVSD) at discharge.

Materials and methods: Two hundred and four consecutive patients with ST-segment-elevation myocardial infarction (STEMI) were prospectively enrolled into the study. CRP plasma concentrations were measured before reperfusion, 24 h after admission and at discharge with an ultra-sensitive latex immunoassay.

Results: CRP concentration increased significantly during the first 24 h of hospitalization (2.4 ± 1.9 vs. 15.7 ± 17.0 mg/L; p < 0.001) and persisted elevated at discharge (14.7 ± 14.7 mg/L), mainly in 57 patients with LVSD (2.4 ± 1.8 vs. 25.0 ± 23.4 mg/L; p < 0.001; CRP at discharge 21.9 ± 18.6 mg/L). The prevalence of LVSD was significantly increased across increasing tertiles of CRP concentration both at 24 h after admission (13.2 vs. 19.1 vs. 51.5 %; p < 0.0001) and at discharge (14.7 vs. 23.5 vs. 45.6 %; p < 0.0001). Multivariate analysis demonstrated CRP concentration at discharge to be an independent marker of early LVSD (odds ratio of 1.38 for a 10 mg/L increase, 95 % confidence interval 1.01-1.87; p < 0.04).

Conclusion: Measurement of CRP plasma concentration at discharge may be useful as a marker of early LVSD in patients after a first STEMI.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Angioplasty, Balloon, Coronary
  • Anti-Arrhythmia Agents / therapeutic use
  • Antihypertensive Agents / therapeutic use
  • Aspirin / therapeutic use
  • Biomarkers / blood
  • C-Reactive Protein / analysis*
  • Clopidogrel
  • Female
  • Heparin / therapeutic use
  • Humans
  • Male
  • Metoprolol / therapeutic use
  • Middle Aged
  • Myocardial Infarction / blood*
  • Myocardial Infarction / diagnosis
  • Myocardial Infarction / therapy
  • Perindopril / therapeutic use
  • Platelet Aggregation Inhibitors / therapeutic use
  • Prospective Studies
  • Risk Factors
  • Ticlopidine / analogs & derivatives
  • Ticlopidine / therapeutic use
  • Ventricular Dysfunction, Left / blood*
  • Ventricular Dysfunction, Left / diagnosis
  • Ventricular Dysfunction, Left / therapy

Substances

  • Anti-Arrhythmia Agents
  • Antihypertensive Agents
  • Biomarkers
  • Platelet Aggregation Inhibitors
  • Heparin
  • C-Reactive Protein
  • Clopidogrel
  • Metoprolol
  • Ticlopidine
  • Aspirin
  • Perindopril